First study of IMC-S118AI in adults with type 1 diabetes
Tests the safety of IMC-S118AI at rising doses in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Study of IMC-S118AI in Type 1 Diabetes
Key facts
- Where
- Graz, AustriaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07493122, who can take part
Where in Austria
- Medical University of GrazGraz, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immunocore Ltd
- Trial code
- NCT07493122EU 2025-524449-28-00
- Record updated
- 25 March 2026
- Original description
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.Read full original descriptionShow less
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Inclusion: Body mass index (BMI): 18 to 25 kg/m2; History of a diagnosis of T1D; HLA type: HLA-A*02:01; Shows signs of remaining beta-cell function.
Exclusion: Prior treatment with immunomodulating therapy for T1D; Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes); History of recurrent hypoglycaemia due to non-compliance with insulin regimens; Have a history of cardiovascular disease or impaired cardiac function; Current diagnosis of a malignancy or any history of malignancy.